← All organizations
Highest phase reached
Phase 3
First clinical trial
Oct 1, 2006First marketed drug
Mar 10, 2021First NDA
Mar 10, 2021Last known activity
Jan 31, 2024
Timeline
Drugs by trial phase (24 distinct, 46 trials)
Phase 3 (5 own, 0 via acquisition)
Phase 2 (12 own, 0 via acquisition)
Phase 1 (7 own, 0 via acquisition)
Indications
Studied for
- Breast Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Colorectal Neoplasms
- Fallopian Tube Neoplasms
- Gastrointestinal Neoplasms
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Liver Diseases
- Liver Neoplasms
- Lung Neoplasms
- Lymphoma
- Multiple Myeloma
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Plasma Cell
- Neoplasms, Second Primary
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Respiratory Tract Neoplasms
- Sarcoma
- Squamous Cell Carcinoma of Head and Neck
- Triple Negative Breast Neoplasms
Marketed drugs (1)
Recent trials (50)
- NCT06053658CollaboratorPhase 2Jan 31, 2024
- NCT06064877Lead sponsorPhase 3Nov 30, 2023
- NCT05865535Lead sponsorPhase 1Jun 13, 2023
- NCT05000294CollaboratorPhase 1/Phase 2Nov 3, 2021
- NCT04987203Lead sponsorPhase 3Sep 9, 2021
- NCT04815551Lead sponsorPhase 1Feb 22, 2021
- NCT04100330Lead sponsorPhase 2Dec 16, 2019
- NCT03970616Lead sponsorPhase 1/Phase 2Aug 31, 2019
- NCT03316599CollaboratorPhase 1Jan 17, 2018
- NCT03136627Lead sponsorPhase 1/Phase 2Mar 22, 2017
- NCT02627963Study directorPhase 3Apr 1, 2016
- NCT02627963Lead sponsorPhase 3Apr 1, 2016
- NCT02277184CollaboratorPhase 1Sep 1, 2015
- NCT02277197CollaboratorPhase 1Aug 1, 2015
- NCT02109627CollaboratorPhase 1Jan 1, 2015
Details
- Founded
- Cambridge, Massachusetts, US Jan 1, 2003
- First NDA
- Mar 10, 2021
- Last known activity
- Jan 31, 2024